{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T11:18:17Z","timestamp":1790162297806,"version":"4.1.0"},"reference-count":13,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T00:00:00Z","timestamp":1694131200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Polish National Agency for Academic Exchange","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Meyers Scholarship Endowment"},{"name":"Fred Hutchinson Cancer"},{"name":"Center"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201600015C"],"award-info":[{"award-number":["HHSN272201600015C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201600015C"],"award-info":[{"award-number":["HHSN272201600015C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI163090"],"award-info":[{"award-number":["AI163090"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL147011"],"award-info":[{"award-number":["HL147011"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A systematic review of randomized and observational studies from 2013 to 2023 demonstrated that antiviral preemptive therapy started at cytomegalovirus viral load thresholds between 2 and 3 log10 IU\/mL was associated with similar cytomegalovirus disease rates. Thus, viral thresholds in this range appear to effectively protect patients not receiving prophylaxis.<\/jats:p>","DOI":"10.1093\/infdis\/jiad386","type":"journal-article","created":{"date-parts":[[2023,9,8]],"date-time":"2023-09-08T17:28:40Z","timestamp":1694194120000},"page":"1435-1439","source":"Crossref","is-referenced-by-count":27,"title":["Cytomegalovirus Viral Load Threshold to Guide Preemptive Therapy in Hematopoietic Cell Transplant Recipients: Correlation With Cytomegalovirus Disease"],"prefix":"10.1093","volume":"229","author":[{"given":"Alicja","family":"Sadowska-Klasa","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Department of Hematology and Transplantology, Medical University of Gdansk , Gdansk , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy M","family":"Leisenring","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-9025","authenticated-orcid":false,"given":"Ajit P","family":"Limaye","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Boeckh","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center , Seattle, Washington , USA"},{"name":"Division of Allergy and Infectious Diseases, Department of Medicine, University of Washington , Seattle, Washington , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,9,8]]},"reference":[{"key":"2024051515163834900_jiad386-B1","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","article-title":"Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation","volume":"377","author":"Marty","year":"2017","journal-title":"N Engl J Med"},{"key":"2024051515163834900_jiad386-B2","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1093\/cid\/ciw370","article-title":"Are we there yet? impact of the first international standard for cytomegalovirus DNA on the harmonization of results reported on plasma samples","volume":"63","author":"Preiksaitis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2024051515163834900_jiad386-B3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2024051515163834900_jiad386-B4","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa1303688","article-title":"CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation","volume":"369","author":"Marty","year":"2013","journal-title":"N Engl J Med"},{"key":"2024051515163834900_jiad386-B5","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.bbmt.2018.09.038","article-title":"A randomized, double-blind, placebo-controlled phase 3 trial of oral brincidofovir for cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplantation","volume":"25","author":"Marty","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024051515163834900_jiad386-B6","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/S2352-3026(15)00289-6","article-title":"Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study","volume":"3","author":"Green","year":"2016","journal-title":"Lancet Haematol."},{"key":"2024051515163834900_jiad386-B7","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1016\/j.bbmt.2020.07.002","article-title":"Letermovir prophylaxis decreases burden of cytomegalovirus (CMV) in patients at high risk for CMV disease following hematopoietic cell transplant","volume":"26","author":"Johnsrud","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024051515163834900_jiad386-B8","doi-asserted-by":"crossref","first-page":"e13866","DOI":"10.1111\/ctr.13866","article-title":"Clinical \u201creal-world\u201d experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients","volume":"34","author":"Anderson","year":"2020","journal-title":"Clin Transplant"},{"key":"2024051515163834900_jiad386-B9","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of preemptive therapy for cytomegalovirus on toxicities after allogeneic hematopoietic cell transplantation in clinical practice: a retrospective single-center cohort study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"2024051515163834900_jiad386-B10","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1007\/s00277-020-04362-2","article-title":"Letermovir prophylaxis is effective in preventing cytomegalovirus reactivation after allogeneic hematopoietic cell transplantation: single-center real-world data","volume":"100","author":"Derigs","year":"2021","journal-title":"Ann Hematol"},{"key":"2024051515163834900_jiad386-B11","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/bloodadvances.2022009112","article-title":"Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantation","volume":"7","author":"Ueda Oshima","year":"2023","journal-title":"Blood Adv"},{"key":"2024051515163834900_jiad386-B12","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1086\/339329","article-title":"Definitions of cytomegalovirus infection and disease in transplant recipients","volume":"34","author":"Ljungman","year":"2002","journal-title":"Clin Infect Dis"},{"key":"2024051515163834900_jiad386-B13","article-title":"Impact of fragmentation on commutability of Epstein-Barr virus and cytomegalovirus quantitative standards","volume":"58","author":"Hayden","year":"2020","journal-title":"J Clin Microbiol"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiad386\/51779252\/jiad386.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/5\/1435\/57674721\/jiad386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/229\/5\/1435\/57674721\/jiad386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,15]],"date-time":"2024-05-15T15:17:09Z","timestamp":1715786229000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/229\/5\/1435\/7264774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":13,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,9,8]]},"published-print":{"date-parts":[[2024,5,15]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiad386","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"value":"0022-1899","type":"print"},{"value":"1537-6613","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,5,15]]},"published":{"date-parts":[[2023,9,8]]}}}